
NYSEHealthcareMedical - Instruments & Supplies
最新データ
$212.78
+$0.10 · +0.05%
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
前日終値
$212.78
+$0.10 · +0.05%
日中の時刻はETです。市場データは遅延する場合があります。
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
日中レンジ
現在 $212.78
52週レンジ
現在 $212.78
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
73
割安
センチメント
68
強気
リスク
26
中程度のリスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
日中レンジ
現在 $212.78
52週レンジ
現在 $212.78
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 194.57億 USD | 218.39億 USD | 201.78億 USD | 193.72億 USD | 188.7億 USD |
| 売上原価 | 102.43億 USD | 119.15億 USD | 110.53億 USD | 112.02億 USD | 103.93億 USD |
| 粗利益 | 92.14億 USD | 99.24億 USD | 91.25億 USD | 81.7億 USD | 84.77億 USD |
| 研究開発 | 9.88億 USD | 12.64億 USD | 11.9億 USD | 12.37億 USD | 12.56億 USD |
| 販売・一般管理 | 49.65億 USD | 52.77億 USD | 48.57億 USD | 47.19億 USD | 47.09億 USD |
| 営業費用 | 69.58億 USD | 73.47億 USD | 67.28億 USD | 60.59億 USD | 61.95億 USD |
| 受取利息 | 2700万 USD | 3800万 USD | 1.63億 USD | 4900万 USD | 1600万 USD |
| 支払利息 | 5.64億 USD | 6.13億 USD | 5.28億 USD | 4.52億 USD | 3.98億 USD |
| 減価償却費と償却費 | 22.38億 USD | 24.62億 USD | 22.86億 USD | 22.88億 USD | 22.29億 USD |
| 営業利益 | 22.56億 USD | 25.78億 USD | 23.97億 USD | 21.11億 USD | 22.82億 USD |
| 純利益 | 11.46億 USD | 16.78億 USD | 17.05億 USD | 14.84億 USD | 17.79億 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
分割調整後の1株当たりの年間現金分配金。
$3.2783
2025年(通年)+27.3% 以来 2021
2026年(一部):$3.15
$2.5743
2,021
$2.7491
2,022
$2.892
2,023
$3.0582
2,024
$3.2783
2,025
$3.15
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当予定 | 2026年12月10日 | $1.06Quarterly | 2026年12月10日 | 2026年12月31日 |
配当 | 2026年9月9日 | $1.05Quarterly | 2026年9月9日 | 2026年9月30日 |
配当 | 2026年6月9日 | $1.05Quarterly | 2026年6月9日 | 2026年6月30日 |
配当 | 2026年3月10日 | $1.05Quarterly | 2026年3月10日 | 2026年3月31日 |
配当 | 2025年12月8日 | $1.05Quarterly | 2025年12月8日 | 2025年12月31日 |
配当 | 2025年9月8日 | $1.04Quarterly | 2025年9月8日 | 2025年9月30日 |
配当落ち 2026年12月10日
$1.06
Quarterly
2026年12月10日基準 · 支払日 2026年12月31日
配当落ち 2026年9月9日
$1.05
Quarterly
2026年9月9日基準 · 支払日 2026年9月30日
配当落ち 2026年6月9日
$1.05
Quarterly
2026年6月9日基準 · 支払日 2026年6月30日
配当落ち 2026年3月10日
$1.05
Quarterly
2026年3月10日基準 · 支払日 2026年3月31日
配当落ち 2025年12月8日
$1.05
Quarterly
2025年12月8日基準 · 支払日 2025年12月31日
配当落ち 2025年9月8日
$1.04
Quarterly
2025年9月8日基準 · 支払日 2025年9月30日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T1116.54億0.09%119.93兆 JPY0.09%¥113,700-3.19%
Vanguard S&P 500 ETFVOO14.32億0.08%1兆 USD0.03%$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI13.5億0.07%6893億 USD0.03%$340.02-3.52%
Vanguard Morningstar Mid-Cap ETFVO11.51億0.52%1074億 USD0.03%$76.25-2.22%
iShares Core S&P 500 ETFIVV7.8億0.10%8034.1億 USD0.03%$693.71-3.52%
State Street SPDR S&P 500 ETFSPY7.04億0.09%7563.79億 USD0.09%$689.81-3.64%
Vanguard Morningstar Value ETFVTV5.18億0.19%1959億 USD0.03%$214.22-1.62%
State Street Health Care Select Sector SPDR ETFXLV4.23億0.90%469.2億 USD0.08%$177.24-0.12%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。